No Data
No Data
Hainan Poly Pharm (SZSE:300630) Has A Somewhat Strained Balance Sheet
Hainan Poly Pharm (300630.SZ) has received an administrative penalty decision from the Hainan Securities Regulatory Bureau.
Hainan Poly Pharm (300630.SZ) announced that the company and related parties received supervision and management committee of China Securities Regulatory Commission in China.
Hainan Poly Pharm Gets Nod to Trial Tumor Drug
Does The Market Have A Low Tolerance For Hainan Poly Pharm. Co., Ltd's (SZSE:300630) Mixed Fundamentals?
Annual report "difficult birth"! Hakuba pharmaceutical stocks receive fines and are once again put on file, with a 20% plummet upon resumption of trading!
The company has been investigated by the China Securities Regulatory Commission for the second time this year.
Hainan Poly Pharm (300630.SZ): Currently under investigation by the China Securities Regulatory Commission.
Hainan Poly Pharm (300630.SZ) announced that the company has received a Notice of Filing from the China Securities Regulatory Commission (CSRC) due to suspected violation of securities laws and regulations.
No Data